Skip to main content
Premium Trial:

Request an Annual Quote

LifeLabs Medical Laboratory Services Adopts Natera's Panorama NIPT

NEW YORK (GenomeWeb) – LifeLabs Medical Laboratory Services is offering Natera's Panorama noninvasive prenatal test at its genetics laboratory in Toronto, Natera said this week.

The Canadian lab services provider has adopted Natera's proprietary test technology and its cloud-based software platform, Constellation, which provides access to Natera's bioinformatic algorithms.

Following a competitive bidding process, the Ontario Ministry of Health and Long-Term Care has selected LifeLabs to perform the Panorama test and will fund the cost of testing for expectant mothers who are considered high-risk and meet certain criteria.

Using its algorithms, Natera said, partner laboratories around the world can now develop and validate their own clinical genomic assays for applications such as NIPT, noninvasive prenatal paternity testing, and, in the future, liquid biopsy assays for oncology.

The Constellation platform meets rigorous patient privacy standards and is highly scalable to accommodate the growing demand for genetic testing, according to Natera.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.